Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Abivertinib in Relapsed/Refractory B-Cell Lymphoma
NCT03060850Phase 1Unknown
- Sponsor
- ACEA Therapeutics
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abivertinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 5 more, sponsored by ACEA Therapeutics. Primary endpoint: Recommended Phase 2 Dose. Status: unknown.
02
Drugs
abivertinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03060850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060850.